Evidence map›Paper›PMID 34334103›Full record

ArticleBioengineered2021

Diagnostic and prognostic value of microRNA-2355-3p and contribution to the progression in lung adenocarcinoma.

Yanan Zhao, Wenlong Zhang, Yang Yang, Enyong Dai, Yuansong Bai

Abstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanan ZhaoDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Wenlong ZhangDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Yang YangDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Enyong DaiDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Yuansong BaiDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.ORCID 0000-0002-3596-0138

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to delve into the clinical significance and biological function of miR-2355-3p in LUAD. Tissues and blood samples from 116 LUAD patients and blood samples of 90 healthy volunteers were collected. The relative expression of miR-2355-3p was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). The receiver operating curve (ROC) was plotted for diagnostic value estimation. Kaplan-Meier survival curves were constructed, and multivariate survival analyses were performed for prognostic value estimation. A luciferase reporter assay was carried out to confirm the interaction of miR-2355-3p and

Indexed as

Adenocarcinoma of LungLung NeoplasmsMicroRNAsCell Line, TumorFemaleHumansMaleMiddle AgedPrognosisMicroRNAsMIRN2355 microRNA, humanbiological functionclinical significancelung adenocarcinomamiR-2355-3pZCCHC14

Identifiers

PMID34334103
PMCPMC8806891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.